Resumen
El fingolimod fue la primera terapia oral para la Esclerosis Múltiple (EM) aprobada en el mundo, como agente modificador de la enfermedad en la forma recurrente remitente (EMRR). Es un profármaco inmunosupresor que muestra una estrecha homología estructural con la esfingosina. La aprobación de su uso tiene soporte científico en los ensayos clínicos colaborativos TRANSFORMS Y FREEDOMS. Los efectos adversos graves reportados durante los estudios, en más de dos pacientes fueron carcinoma basocelular, bradicardia dentro de las primeras seis horas de administración, infección del tracto respiratorio inferior y dos pacientes fallecidos: por encefalitis herpética una, el otro por el virus varicela zóster. Existe riesgo en 0.3% de los casos, de desarrollar edema macular.
Citas
COMPSTON A, COLES A. Multiple Sclerosis. Lancet. 2008; 372:1502-17.
TORO J, CARDENAS S, MARTINEZ CF, URRUTIA J, DIAZ C. Multiple sclerosis in Colombia and other Latin American Countries. Multiple Sclerosis and Related Disorders. 2013; 2:80-9.
NESSLER S, BRÜCK W. Advances in multiple sclerosis research in 2009. J Neurol. 2010; 257:1590-3.
World Health Organization. Atlas: multiple sclerosis resources in the world 2008. 2008; 1-56.
WOLINSKY JS. The diagnosis of primary progressive multiple sclerosis. J Neurol Sci. 2003; 206:145-52.
SAMUELS MA, ROPPER AH. Samuels's Manual of Neurologic Therapeutics. Philadelphia: Lippincott williams & wilkins. 2010:171-91.
FROHMAN EM, RACKE MK, RAINE CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med. 2006; 354:942-55.
PETERSON LK, FUJINAMI RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2007; 184:37-44.
MCQUALTER JL, BERNARD CC. Multiple sclerosis: a battle between destruction and repair. J Neurochem. 2007; 100:295-306.
CHUN J, HARTUNG HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010; 33:91-101.
RIECKMANN P. Socio-economic aspects of aspects of neuroimmunological diseases. J Neurol. 2008; 255:308.
ROSSELLI D, ARIZA JD, ACOSTA T, RUEDA JD. Análisis de impacto presupuestal de la introducción de Fingolimod en el tratamiento de Esclerosis múltiple en Colombia. Acta Neurol Colomb. 2012; 28:4-10.
SANFORD M, LYSENG-WILLIAMSON KA. Subcutaneous recombinant interferon ?-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis. Drugs. 2011; 71:1865-91.
BETASERON [package insert]. Montville, NJ: Bayer Healthcare Pharmaceuticals Inc. 2010.
COPAXONE [package insert]. North wales, PA: Teva Pharmaceuticals USA; February 2009.
TYSABRI [package insert]. South San Francisco, CA: Biogen Idec Inc; 2011.
NOVANTRONE [package insert]. Rockland, MA: Serono, Inc; May 2012.
US Food and Drug Administration (FDA) FDA approves first oral drug to reduce MS relapses [press release] Sep 22. 2010. [Accessed June 1, 2011]. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm.
European Medicines Agency (EMA) Assessment report: Gilenya. Doc Ref: EMA/108602/2011. February 17. 2011. [Accessed June 1, 2011]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/wC500104529.pdf.
COSTANTINO CM, BAECHER-ALLAN C, HAFLER DA. Multiple sclerosis and regulatory T cells. J Clin Immunol. 2008; 28:697-706.
BRINKMANN V, DAVIS M, HEISE C, ALBERT R, COTTENS S, HOF R, ET AL. J Biol Chem. 2002; 277:21453-7.
COHEN J, CHUN J. Mechanism of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011; 69:759-77.
FUJITA T, INOUE K, YAMAMOTO S, IKU-MOTO T, SASAKI S, TOYAMA R, ET AL. Fungal metabolites. Part 12. Potent immunosuppressant, 14-deoxomyriocin, (2S,3R,4R)[E]2amino-3,4-dihydroxy-2-hydroxymethyleicos-6-enoic acid and structure-activity relationships of myriocin derivatives. J ANTIBIOTIC (TOKIO). 1994; 47:216-24.
KAPPOS L, ANTEL J, COMI G, MONTALBAN X, O'CONNOR P, POLMAN CH, ET AL. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006; 355:1124-40.
COMI G, O'CONNOR P, MONTALBAN X, ANTE J, RADUE EW, KARLSSON G, ET AL. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010; 16:197-207.
MATLOUBIAN M, LO CG, CINAMON G, LESNESKI M, XU Y, BRINKMANN V, ALLENDE M, ET AL. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004; 427:355-60.
FOSTER CA, MECHTCHERIAKOVA D, STORCH MK, BALATONI B, HOWARD L, BORNANCIN F, ET AL. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain barrier damage. Brain Pathol. 2009; 19:254-66.
BALATONI B, STORCH MK, SWOBODA EM, SCHÖNBORN V, KOZIEL A, LAMBROU G, ET AL. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull. 2007; 74:307-16.
ROSSI S, CAVASINNI F, DE CHIARA V, ET AL. Fingolimod protects synaptic transmission in experimental autoimmune encephalomyelitis. Abstract P595. Mult Scler. 2009; 15:S178.
BRINKMANN V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009; 158:1173-82.
ROSSI S, DE CHIARA V, MOTTA C, ET AL. Fingolimod treatment prevents the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis (P880). Mult Scler. 2010; 16; S309S310.
ANTHONY DC, SIBSON NR, LEPPERT D, PIANI MEIER D. Fingolimod (FTY720) therapy reduces demyelination and microglial activation in a focal delayed-type hypersensitivity model of multiple sclerosis during the remission phase (P814). Mult Scler. 2010; 16:S283-S284.
DAVID O, KOVARIK J, SCHMOUDER R. Clinical pharmacokinetics of fingolimod. Clin Pharmacoquinet. 2012; 51:15-28.
FRANCIS G, KAPPOS L, O'CONNOR P, ET AL. Lymphocytes and fingolimod - temporal pattern and relationship with infections. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 2010 Gothenburg, Sweden.
COHEN J, BARKHOF F, COMI G, HARTUNG HP, KHATRI BO, MONTALBAN X, ET AL. Oral Fingolimod or intramuscular interferon for multiple sclerosis. N Engl J Med. 2010; 362:402-15.
KAPPOS L, RADUE EW, O'CONNOR P, POLMAN C, HOHLFELD R, CALABRESI P, ET AL. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362:287-401.
HARTUNG HP, COMI G, BARKHOF F, ET AL. Sustained benefit of continuous therapy with fingolimod compared with switching to fingolimod after 1 year of treatment with interferon ?-1a in patients with relapsing-remitting multiple sclerosis: results of TRANSFORMS 2 year extension study. Mult Scler. 2010; 10:S282.
COHEN J, MONTALBAN X, PELLETIER J, ET AL. Efficacy and safety of fingolimod in patients switched from intramuscular interferon ?-1a: results from the TRANSFORMS extension study. ECTRIMS: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 2010. Gothenburg, Sweden.
COHEN J, RADUE EW, BARKHOF, ET AL. Fingolimod-effect on brain atrophy and clinical/ MRI correlations in three phase 3 studies-TRANSFORMS, FREEDOMS and FREEDOMS II. Platform presentation at: 65th Annual Meeting of the American Academy of Neurology 2013. San Diego, USA. Presentation S51.006.
https://www.gilenyapregnancyregistry.com/
Novartis Pharmaceutical Corporation. Prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf. Accessed June 1, 2011.
FREEDMAN MS. Approach to initiating and switching disease modifying therapies: use of newer and older agents, 7HC.012. 65th Annual Meeting of the American Academy of Neurology 2013. San Diego, USA.
STEINER JF, PROCHAZKA AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997; 50:105-16.
REYNOLDS MW, REEJIS S, SEAMAN CH, KITTY RAJAGOPALAN. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Current Medical Research & Opinion. 2010; 26:663-74.
RICH SR, COLEMAN IC, COOK R, HUM DS, JOHNSON B, MAVES T, ET AL. Stepped- care approach to treating MS: a managed care treatment algorithm. J Manag Care Pharm. 2004; 10:S26-32.
CLERICO M, BAEBERO P, CONTESSA G, FERRERO C, DURELLI L. Adherence to interferon ? treatment and results of therapy switching. J Neurol Sci. 2007; 259:104-8.
TREMLETT H, VAN DER MEI I, PITTAS F, BIZZARD L, PALEY G, TAYLOR B, ET AL. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008; 17:565-76.
MOSEES H. Therapy of multiple sclerosis, 8SM.006. 65th Annual Meeting of the American Academy of Neurology 2013. San Diego, USA.
O'CONNOR P, WOLINSKY JS, CONFAVREUX C, COMI G, KAPPOS L, OLSSON TP, ET AL. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011; 365:1293-303.
FOX J, MILLER D, PHILLIPS J , HUTCHINSON M, HAVRDOVA E, KITA M, ET AL. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012; 367:1087-97.
AGASHIVALA N, ET AL. Time to discontinuation for Fingolimod and other first-line disease modifying therapies, abstract P717. ECTRIMS 27th Congress 2012. Lyon, France.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.